{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:59:35Z","timestamp":1771919975631,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Endemic regions of cutaneous leishmaniasis (CL) and intestinal helminthiasis overlap. CL treatment with systemic pentavalent antimonial drugs (Sb5+) fails in 10%\u201330% of patients. The study objective was to assess the etiological role of intestinal helminthiasis in CL treatment failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An unmatched case\u2013control study was done in 4 CL treatment sites in Peru in 2012\u20132015. Cases were CL patients with Sb5+ treatment failure; controls were CL patients with Sb5+ treatment success. Patients with a parasitologically confirmed CL diagnosis who had received supervised Sb5+ treatment and could be classified as cases or controls were eligible. The main exposure variables were intestinal helminthiasis and strongyloidiasis, diagnosed through direct examination, rapid sedimentation, Baermann, Kato-Katz, or agar culture of stool samples. Additional exposure variables were other infections (HIV, human T-lymphotropic virus 1, tuberculosis, hepatitis B, intestinal protozoa) and noninfectious conditions (diabetes, renal insufficiency, and immunosuppressive medication). Age, gender, CL history, probable exposure place, and Leishmania species were treated as potential confounders in multiple logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 94 case and 122 control subjects. Overall, infectious and noninfectious comorbidities were frequent both among cases (64%) and controls (71%). The adjusted odds ratio (OR) for the association between any intestinal helminth infection and CL treatment failure was 0.65 (95% confidence interval [CI], 0.30\u20131.38), and the adjusted OR for the association between strongyloidiasis and CL treatment failure was 0.34 (95% CI, 0.11\u20130.92).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the Peruvian setting, high Sb5+ treatment failure rates are not explained by intestinal helminthiasis. On the contrary, strongyloidiasis had a protective effect against treatment failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa155","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T13:20:50Z","timestamp":1590585650000},"source":"Crossref","is-referenced-by-count":6,"title":["A Case\u2013Control Study on the Association Between Intestinal Helminth Infections and Treatment Failure in Patients With Cutaneous Leishmaniasis"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-3962","authenticated-orcid":false,"given":"Dalila Y","family":"Mart\u00ednez","sequence":"first","affiliation":[{"name":"Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru"},{"name":"Departamento de Enfermedades Infecciosas, Tropicales y Dermatol\u00f3gicas, Hospital Cayetano Heredia, Lima, Peru"},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium"},{"name":"Instituto de Medicina Tropical \u201cAlexander von Humboldt,\u201d Universidad Peruana Cayetano Heredia, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Llanos-Cuentas","sequence":"first","affiliation":[{"name":"Departamento de Enfermedades Infecciosas, Tropicales y Dermatol\u00f3gicas, Hospital Cayetano Heredia, Lima, Peru"},{"name":"Instituto de Medicina Tropical \u201cAlexander von Humboldt,\u201d Universidad Peruana Cayetano Heredia, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Dujardin","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical, Biomedical, and Veterinary Sciences, University of Antwerp, Antwerp, Belgium"},{"name":"Institute of Tropical Medicine, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Polman","sequence":"first","affiliation":[{"name":"Institute of Tropical Medicine, Antwerp, Belgium"},{"name":"Department of Health Sciences, VU University, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Adaui","sequence":"first","affiliation":[{"name":"Instituto de Medicina Tropical \u201cAlexander von Humboldt,\u201d Universidad Peruana Cayetano Heredia, Lima, Peru"},{"name":"Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias y Filosof\u00eda, Universidad Peruana Cayetano Heredia, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen","family":"Boelaert","sequence":"first","affiliation":[{"name":"Institute of Tropical Medicine, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristien","family":"Verdonck","sequence":"first","affiliation":[{"name":"Instituto de Medicina Tropical \u201cAlexander von Humboldt,\u201d Universidad Peruana Cayetano Heredia, Lima, Peru"},{"name":"Institute of Tropical Medicine, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"2020052709200402100_CIT0001","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"2020052709200402100_CIT0002","volume-title":"Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases","author":"World Health Organization","year":"2010"},{"key":"2020052709200402100_CIT0003","volume-title":"Leishmaniasis: Epidemiological Report of the Americas","author":"\/Pan American Health Organization","year":"2019"},{"key":"2020052709200402100_CIT0004","first-page":"557","article-title":"Global leishmaniasis update, 2006\u20132015: a turning point in leishmaniasis surveillance","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"2020052709200402100_CIT0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"2020052709200402100_CIT0006","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"2020052709200402100_CIT0007","doi-asserted-by":"crossref","first-page":"e0149697","DOI":"10.1371\/journal.pone.0149697","article-title":"The cure rate after placebo or no therapy in American cutaneous leishmaniasis: a systematic review and meta-analysis","volume":"11","author":"Cota","year":"2016","journal-title":"PLoS One"},{"key":"2020052709200402100_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2007.08.003","article-title":"Mucosal leishmaniasis. Current scenario and prospects for treatment","volume":"105","author":"Amato","year":"2008","journal-title":"Acta Trop"},{"key":"2020052709200402100_CIT0009","volume-title":"Manual de Procedimientos Para Vigilancia y Control de las Leishmaniasis en las Am\u00e9ricas","year":"2019"},{"key":"2020052709200402100_CIT0010","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1086\/518041","article-title":"Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis","volume":"195","author":"Arevalo","year":"2007","journal-title":"J Infect Dis"},{"key":"2020052709200402100_CIT0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/infdis\/jiv354","article-title":"Association of the endobiont double-stranded RNA virus LRV1 with treatment failure for human leishmaniasis caused by Leishmania braziliensis in Peru and Bolivia","volume":"213","author":"Adaui","year":"2016","journal-title":"J Infect Dis"},{"key":"2020052709200402100_CIT0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiv355","article-title":"Presence of Leishmania RNA virus 1 in Leishmania guyanensis increases the risk of first-line treatment failure and symptomatic relapse","volume":"213","author":"Bourreau","year":"2016","journal-title":"J Infect Dis"},{"key":"2020052709200402100_CIT0013","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0974-777X.68528","article-title":"Human immunodeficiency virus and leishmaniasis","volume":"2","author":"Ezra","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"2020052709200402100_CIT0014","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/clinids\/23.4.836","article-title":"Concurrent mucosal leishmaniasis and pulmonary tuberculosis","volume":"23","author":"Escobar","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020052709200402100_CIT0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1086\/376632","article-title":"American cutaneous leishmaniasis, lepromatous leprosy, and pulmonary tuberculosis coinfection with downregulation of the T-helper 1 cell response","volume":"37","author":"Delobel","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020052709200402100_CIT0016","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1128\/CMR.05040-11","article-title":"Helminth infections and host immune regulation","volume":"25","author":"McSorley","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2020052709200402100_CIT0017","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1086\/509808","article-title":"Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis","volume":"195","author":"O\u2019Neal","year":"2007","journal-title":"J Infect Dis"},{"key":"2020052709200402100_CIT0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.actatropica.2015.10.015","article-title":"Intestinal helminth coinfection is associated with mucosal lesions and poor response to therapy in American tegumentary leishmaniasis","volume":"154","author":"Azeredo-Coutinho","year":"2016","journal-title":"Acta Trop"},{"key":"2020052709200402100_CIT0019","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4269\/ajtmh.2011.10-0423","article-title":"Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis","volume":"84","author":"Newlove","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020052709200402100_CIT0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-3024.2010.01273.x","article-title":"Efficient control of Leishmania and Strongyloides despite partial suppression of nematode-induced Th2 response in co-infected mice","volume":"33","author":"Kolbaum","year":"2011","journal-title":"Parasite Immunol"},{"key":"2020052709200402100_CIT0021","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-3024.2002.00473.x","article-title":"Schistosomiasis delays lesion resolution during Leishmania major infection by impairing parasite killing by macrophages","volume":"24","author":"La Flamme","year":"2002","journal-title":"Parasite Immunol"},{"key":"2020052709200402100_CIT0022","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm","year":"2007","journal-title":"BMJ"},{"key":"2020052709200402100_CIT0023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.exppara.2013.03.026","article-title":"An approach for interlaboratory comparison of conventional and real-time PCR assays for diagnosis of human leishmaniasis","volume":"134","author":"Cruz","year":"2013","journal-title":"Exp Parasitol"},{"key":"2020052709200402100_CIT0024","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1086\/524042","article-title":"Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru","volume":"46","author":"Llanos-Cuentas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020052709200402100_CIT0025","doi-asserted-by":"crossref","first-page":"e0006141","DOI":"10.1371\/journal.pntd.0006141","article-title":"Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation","volume":"12","author":"Olliaro","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2020052709200402100_CIT0026","volume-title":"Parasitic Diseases. 6th ed","author":"Despommier","year":"2017"},{"key":"2020052709200402100_CIT0027","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1128\/IAI.70.2.427-433.2002","article-title":"Immunology of parasitic helminth infections","volume":"70","author":"MacDonald","year":"2002","journal-title":"Infect Immun"},{"key":"2020052709200402100_CIT0028","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/JCM.05061-11","article-title":"Leishmania (Viannia) species identification on clinical samples from cutaneous leishmaniasis patients in Peru: assessment of a molecular stepwise approach","volume":"50","author":"Veland","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020052709200402100_CIT0029","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s10096-011-1463-z","article-title":"Three new sensitive and specific heat-shock protein 70 PCRs for global Leishmania species identification","volume":"31","author":"Montalvo","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020052709200402100_CIT0030","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1128\/JCM.00208-13","article-title":"Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters","volume":"51","author":"Jara","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020052709200402100_CIT0031","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.01513-08","article-title":"Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials","volume":"77","author":"Maurer-Cecchini","year":"2009","journal-title":"Infect Immun"},{"key":"2020052709200402100_CIT0032","doi-asserted-by":"crossref","first-page":"e0007265","DOI":"10.1371\/journal.pntd.0007265","article-title":"Helminth mediated modulation of the systemic and mycobacterial antigen - stimulated cytokine profiles in extra-pulmonary tuberculosis","volume":"13","author":"Kathamuthu","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2020052709200402100_CIT0033","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.it.2016.07.005","article-title":"Helminth-tuberculosis co-infection: an immunologic perspective","volume":"37","author":"Babu","year":"2016","journal-title":"Trends Immunol"},{"key":"2020052709200402100_CIT0034","doi-asserted-by":"crossref","first-page":"e42901","DOI":"10.1371\/journal.pone.0042901","article-title":"The impact of asymptomatic helminth co-infection in patients with newly diagnosed tuberculosis in North-West Ethiopia","volume":"7","author":"Abate","year":"2012","journal-title":"PLoS One"},{"key":"2020052709200402100_CIT0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1756-3305-6-79","article-title":"Co-infection of tuberculosis and parasitic diseases in humans: a systematic review","volume":"6","author":"Li","year":"2013","journal-title":"Parasit Vectors"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/5\/ofaa155\/33315067\/ofaa155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/5\/ofaa155\/33315067\/ofaa155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T13:21:03Z","timestamp":1590585663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa155\/5836320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa155","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]},"article-number":"ofaa155"}}